These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18668689)

  • 1. Shifting patterns of inhaled antibiotic use in cystic fibrosis.
    Moskowitz SM; Silva SJ; Mayer-Hamblett N; Pasta DJ; Mink DR; Mabie JA; Konstan MW; Wagener JS;
    Pediatr Pulmonol; 2008 Sep; 43(9):874-81. PubMed ID: 18668689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled antibiotics for lower airway infections.
    Quon BS; Goss CH; Ramsey BW
    Ann Am Thorac Soc; 2014 Mar; 11(3):425-34. PubMed ID: 24673698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
    Dasenbrook EC; Konstan MW; VanDevanter DR
    J Cyst Fibros; 2015 May; 14(3):370-5. PubMed ID: 25496726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany.
    Naehrig S; Schulte-Hubbert B; Hafkemeyer S; Hammermann J; Dumke M; Sieber S; ; Naehrlich L
    Pulm Pharmacol Ther; 2023 Jun; 80():102214. PubMed ID: 37003541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Ryan G; Jahnke N; Remmington T
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
    Stelmach I; Korzeniewska A; Stelmach W
    Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled antibiotics for long-term therapy in cystic fibrosis.
    Ryan G; Singh M; Dwan K
    Cochrane Database Syst Rev; 2011 Mar; (3):CD001021. PubMed ID: 21412868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
    Langan KM; Kotsimbos T; Peleg AY
    Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
    Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
    Antoniu S
    Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
    Hodson ME; Gallagher CG; Govan JR
    Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis.
    Florescu MC; Lyden E; Murphy PJ; Florescu DF; Fillaus J
    Hemodial Int; 2012 Jul; 16(3):414-9. PubMed ID: 22469183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New clinical evidence from the European tobramycin trial in cystic fibrosis.
    Hodson ME; Gallagher CG
    J Cyst Fibros; 2002 Dec; 1(Suppl 2):199-202. PubMed ID: 15463835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
    Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
    Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
    Elborn JS; Hodson M; Bertram C
    J Cyst Fibros; 2009 May; 8(3):211-7. PubMed ID: 19372063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.